Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (91-100 of 208) with videos related to

Pageof 21
Sort By:
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
European Journal of Radiology|September 3, 2024
PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancerDivya Yadav, Silvina P Dutruel, Elisabeth O'Dwyer, et al.
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 25, 2014
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancerShankar Vallabhajosula, Anastasia Nikolopoulou, John W Babich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
European Urology|April 9, 2025
Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, et al.
Neoplasia (New York, N.Y.)|January 30, 2013
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerJuan Miguel Mosquera, Himisha Beltran, Kyung Park, et al.
Nature Genetics|November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinomaBishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
Pageof 21

Showing results (91-100 of 208) with videos related to

Sort By:
Pageof 21
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
European Journal of Radiology|September 3, 2024
PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancerDivya Yadav, Silvina P Dutruel, Elisabeth O'Dwyer, et al.
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 25, 2014
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancerShankar Vallabhajosula, Anastasia Nikolopoulou, John W Babich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
European Urology|April 9, 2025
Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562]Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Thomas A Hope, Emmanuel S Antonarakis, Lisa Bodei, et al.
Neoplasia (New York, N.Y.)|January 30, 2013
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerJuan Miguel Mosquera, Himisha Beltran, Kyung Park, et al.
Nature Genetics|November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinomaBishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
Pageof 21